Last reviewed · How we verify
Atropine Sulfate 03
Atropine sulfate is an anticholinergic agent that blocks muscarinic acetylcholine receptors to inhibit parasympathetic nervous system activity.
Atropine sulfate is an anticholinergic agent that blocks muscarinic acetylcholine receptors to inhibit parasympathetic nervous system activity. Used for Anticholinergic poisoning and organophosphate/nerve agent exposure, Symptomatic bradycardia and heart block, Mydriasis and cycloplegia for ophthalmic examination.
At a glance
| Generic name | Atropine Sulfate 03 |
|---|---|
| Also known as | LPTAT03 |
| Sponsor | LitePharmTech Co., Ltd. |
| Drug class | Anticholinergic agent / Muscarinic antagonist |
| Target | Muscarinic acetylcholine receptors (M1-M5) |
| Modality | Small molecule |
| Therapeutic area | Emergency Medicine, Ophthalmology, Cardiology |
| Phase | Phase 3 |
Mechanism of action
Atropine competitively antagonizes acetylcholine at muscarinic receptors throughout the body, reducing parasympathetic effects on the heart, smooth muscle, and secretory glands. This results in increased heart rate, bronchodilation, reduced secretions, and mydriasis. The sulfate salt formulation enhances solubility and bioavailability for parenteral or oral administration.
Approved indications
- Anticholinergic poisoning and organophosphate/nerve agent exposure
- Symptomatic bradycardia and heart block
- Mydriasis and cycloplegia for ophthalmic examination
- Reduction of salivary, bronchial, and gastric secretions perioperatively
Common side effects
- Tachycardia
- Mydriasis and cycloplegia
- Dry mouth
- Urinary retention
- Constipation
- Confusion or agitation (at high doses)
- Hyperthermia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Atropine Sulfate 03 CI brief — competitive landscape report
- Atropine Sulfate 03 updates RSS · CI watch RSS
- LitePharmTech Co., Ltd. portfolio CI